SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Shawarma and rubble: The paradox of Gaza’s post-war recovery

“Global LPs now assume Israeli founders can operate through geopolitical shocks, volatility, operational chaos, and even war”

Chinese fund: “The Chinese government has imposed a ban on any new investment in Israel”

Innovation or exhaustion? The human cost of tech’s AI reset

Buzz

Most popular

Daily

Weekly

1

Why Apple paid billions for a company with no revenue

2

Valued at $800 million after less than two years, Vega eyes the path blazed by Wiz

3

Google-Wiz deal expected to be cleared by EU following meeting with regulators, report says

4

Israeli startups raise over $1 billion in January, marking best opening month since 2022

5

From secret satellites to civilian services: Israel’s space industry reinvents itself

Entera

4 stories about Entera

Drug Developer Entera Bio Down on Nasdaq Following Amgen Deal

12.12.18|Lilach Baumer

The deal, announced Tuesday, could see Entera receive up to $270 million in aggregate payments

תרופות זירת הבריאות

Entera Bio Gives Nasdaq IPO Another Shot

21.05.18|Dror Reich

This is the fourth time since 2014 that the Jerusalem-based biomed company files for an initial public offering on Nasdaq

תל אביב קו רקיע Tel Aviv Skyline

CTech’s Daily Israeli Tech News Roundup

Israeli investment house to open crypto unit. A closer look at the first company funded by Koch’s new venture capital firm. Intuition Robotics expands funding round, nabbing Samsung as an investor.

נאסד"ק וול סטריט

For the Fourth Time, Entera Bio Tries for Nasdaq IPO

08.01.18|Dror Reich

The Jerusalem-based biomed company plans to raise $55 million, with Oppenheimer & Co. as the sole underwriter